Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=317 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 2 N=85 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…
Phase 3 N=848 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Chemotherapy-Induced Nausea and Vomiting
Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01
Phase 2 N=41 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants
Phase 3 N=690 Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Malignant Neoplasm
Primary: No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and…
Phase 3 N=46 Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Malignant Neoplasm · Nausea · Vomiting
Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98
Phase 3 N=120 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced Nausea and Vomiting
Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397
Phase 3 N=1,021 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
Nausea
Primary: Home Record: Severity of Delayed Nausea — 1.88; 1.65; 1.87; 1.68 units on a scale — p=0.718
Phase 3 N=421 Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1 — 0.696; 0.570…
Phase 3 N=1,015 Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC) — 78.9; 68.5 Percentage of…
Phase 2 N=85 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
Phase 3 N=69 Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Germ Cell Tumors
Primary: Complete Response. — 47; 15 percentage of evaluable subjects
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
Phase 4 N=494 A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
Nausea · Vomiting
Primary: The Percentage of Participants With No Vomiting - Overall Stage — 77.2; 72.0 Percentage of Participants — p=0.191
Phase 3 N=710 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Nausea and Vomiting, Chemotherapy-Induced
Primary: Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately…
Phase 2 N=30 Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Melanoma
Primary: Cumulative Participants Response to Palonosetron — 85; 139; 44; 72 episodes of nausea/vomiting
Phase 2 N=54 Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
Colorectal Cancer · Nausea and Vomiting
Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants
Phase 2 N=43 Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
Malignant Neoplasm
Primary: Complete Response (CR) Defined as no Emesis and no Rescue Therapy — 13 Participants
Phase 2 N=342 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
CINV
Primary: Number of Participants With Delayed Phase Complete Response(CR) — 37; 13; 27; 21 Participants — p=0.004
Phase 2 N=22 Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Nausea With Vomiting Chemotherapy-Induced
Primary: Complete Acute Response — 4; 4; 3 Participants
Phase 2 N=68 Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage
Phase 2 N=136 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
N/A N=30 Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Gastrointestinal Cancer · Nausea Post Chemotherapy
Primary: Percentage of Participants With Control of Vomiting and Rescue Medication Control — 26.9 percentage of participants
Phase 2 N=22 Emend for Multiple-day Emetogenic Chemotherapy
Nausea · Vomiting
Primary: Complete Response (Percentage of Patients) — 84 percentage of participants
Phase 3 N=502 Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
Chemotherapy-Induced Nausea and Vomiting
Primary: Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1 — 54.2; 59.4; 58.6 percentage of patients
Phase 2 N=67 PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant — 4460; 3849; 17340; 7637 ng*hr/mL
Phase 3 N=555 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 70.1; 61.9 percentage of participants — p=0.043